Kidney outcomes with <scp>SGLT2</scp> inhibitors in patients with diabetes and an insulin‐deficient phenotype: A real world analysis
SGLT2i demonstrated substantial kidney protection in insulin-deficient patients, extending benefits beyond type 2 diabetes. These findings highlight SGLT2i as a potential therapeutic option for mitigating DKD in high-risk populations.
Authors
- Rena Pollack (ORCID: https://orcid.org/0000-0001-6771-337X)
- Anat Tsur (ORCID: https://orcid.org/0000-0001-8573-4705)
- Avivit Cahn (ORCID: https://orcid.org/0000-0002-7830-9994)
- Lior Hanoch
Institutions
- Hebrew University of Jerusalem (IL)
- Hadassah Medical Center (IL)
- Clalit Health Services (IL)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-03-14
- DOI
- https://doi.org/10.1111/dom.16329
- Citations
- 3
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 3.88